RITSUKO KOMAKI to Antineoplastic Agents, Alkylating
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Antineoplastic Agents, Alkylating.
Connection Strength
0.021
-
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1312-8.
Score: 0.021